secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0001837607-25-000068
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma makes corporate presentation available; limited specifics disclosed
--------------------------------------------------------------------------------

- Presentation references $3B+ U.S. neurotoxin therapeutic market via biosimilarity approach.
- No financial guidance, pipeline updates, or milestones provided in filing or excerpt.
- CEO Robert Bancroft signs 8-K; presentation may be used in future investor meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000068/0001837607-25-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000068/aeon-20250908x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer